scholarly journals Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting

2005 ◽  
Vol 11 (11) ◽  
pp. 887-892 ◽  
Author(s):  
C. Juan ◽  
O. Gutiérrez ◽  
A. Oliver ◽  
J.I. Ayestarán ◽  
N. Borrell ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Pseudomonas Aeruginosa ◽  
Intensive Care ◽  
Antimicrobial Resistance ◽  
Intensive Care Unit Setting ◽  
Selection Of

scholarly journals Antimicrobial Resistance Profile of MDR & Non-MDR Meropenem-Resistant Pseudomonas aeruginosa Isolates of Patients in Intensive Care Unit of Tertiary Hospital

2021 ◽  
Vol 9 (3) ◽  
pp. 152
Author(s):  
Imaculata Sonia Vidaryo Lameng ◽  
Ni Nyoman Sri Budayanti ◽  
Luh Inta Prilandari ◽  
I Ketut Agus Indra Adhiputra
Keyword(s):  
Intensive Care Unit ◽  
Pseudomonas Aeruginosa ◽  
Intensive Care ◽  
Antimicrobial Resistance ◽  
Empirical Therapy ◽  
Tertiary Hospital ◽  
Clinical Microbiology Laboratory ◽  
Cross Sectional ◽  
Resistance Profile ◽  
Control Programs

Pseudomonas aeruginosa is one of the gram-negative bacteria that causes infection in the Intensive Care Unit (ICU) which is easily resistant. Patients infected with carbapenem-resistant P. aeruginosa are predicted to have a poor prognosis. This study aims to know the resistance profile of meropenem-resistant P. aeruginosa in the ICU. The results of this study can be used as a measure on the success of antimicrobial resistance control, infection control programs and become a reference for empirical therapy in the ICU. This study used a cross-sectional retrospective descriptive research method and was carried out at the Clinical Microbiology Laboratory of Sanglah Hospital Denpasar for three years, from 2018 to 2020. The results showed 38 of the 93 isolates of P. aeruginosa in the ICU were resistant to meropenem and were derived from sputum and urine. The percentage of meropenem-resistant P. aeruginosa isolates was higher in the multi-drug-resistant group and mostly came from sputum specimens. In 2018, Non-MDR meropenem-resistant P. aeruginosa isolates was that 100% sensitive to all other antibiotics used to treat P. aeruginosa infections, including; ceftazidime, cefepime, ciprofloxacin, gentamicin, amikacin, and piperacillin-tazobactam. In 2019 no meropenem-resistant P. aeruginosa isolates were found. In 2020, its sensitivity to antibiotics ceftazidime and piperacillin-tazobactam was 20.0%, ciprofloxacin 60.0% and to antibiotics gentamicin and amikacin 100%. MDR meropenem-resistant P. aeruginosa isolates in 2018 were still sensitive to ceftazidime (15.4%) and amikacin (69.2%) antibiotics, while in 2019 they were only sensitive to amikacin (37.5%). In 2020, P. aeruginosa isolates were sensitive to the antibiotics ceftazidime and cefepime (11.1%), piperacillin-tazobactam (22.2%), and amikacin (88.9%). Amikacin may be the choice of treatment for MDR meropenem-resistant P. aeruginosa.

scholarly journals Risk Factors for Development of Intestinal Colonization with Imipenem-Resistant Pseudomonas aeruginosa in the Intensive Care Unit Setting

2011 ◽  
Vol 32 (7) ◽  
pp. 719-722 ◽  
Author(s):  
Anthony D. Harris ◽  
J. Kristie Johnson ◽  
Kerri A. Thom ◽  
Daniel J. Morgan ◽  
Jessina C. McGregor ◽  
...  
Keyword(s):  
Risk Factors ◽  
Intensive Care Unit ◽  
Pseudomonas Aeruginosa ◽  
Intensive Care ◽  
Potential Risk ◽  
Selective Pressure ◽  
Intensive Care Unit Setting ◽  
Intestinal Colonization ◽  
Potential Risk Factors

Risk factors for development of intestinal colonization by imipenem-resistant Pseudomonas aeruginosa (IRPA) may differ between those who acquire the organism via patient-to-patient transmission versus by antibiotic selective pressure. The aim of this study was to quantify potential risk factors for the development of IRPA not due to patient-to-patient transmission.

scholarly journals Antimicrobial Resistance Prediction in Intensive Care Unit for Pseudomonas Aeruginosa using Temporal Data-Driven Models

2021 ◽  
Vol 6 (5) ◽  
pp. 119
Author(s):  
Àlvar Hernàndez-Carnerero ◽  
Miquel Sànchez-Marrè ◽  
Inmaculada Mora-Jiménez ◽  
Cristina Soguero-Ruiz ◽  
Sergio Martínez-Agüero ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Pseudomonas Aeruginosa ◽  
Intensive Care ◽  
Antimicrobial Resistance ◽  
Data Driven ◽  
Temporal Data ◽  
Resistance Prediction

scholarly journals National Surveillance of Antimicrobial Resistance in Pseudomonas aeruginosa Isolates Obtained from Intensive Care Unit Patients from 1993 to 2002

2004 ◽  
Vol 48 (12) ◽  
pp. 4606-4610 ◽  
Author(s):  
Marilee D. Obritsch ◽  
Douglas N. Fish ◽  
Robert MacLaren ◽  
Rose Jung
Keyword(s):  
Intensive Care Unit ◽  
Pseudomonas Aeruginosa ◽  
Intensive Care ◽  
Antimicrobial Resistance ◽  
The United States ◽  
Treatment Regimens ◽  
Ongoing Surveillance ◽  
Resistance Rates ◽  
Susceptibility Patterns ◽  
Study Database

ABSTRACT Nosocomial infections caused by Pseudomonas aeruginosa in critically ill patients are often difficult to treat due to resistance to multiple antimicrobials. The purpose of this study was to evaluate antimicrobial resistance among P. aeruginosa isolates from intensive care unit patients in the United States from 1993 to 2002 by using the Intensive Care Unit Surveillance Study database. Over the 10-year period, susceptibility of 13,999 nonduplicate isolates of P. aeruginosa was analyzed. From 1993 to 2002, nationwide increases in antimicrobial resistance were greatest for ciprofloxacin, imipenem, tobramycin, and aztreonam. Rates of multidrug resistance (resistance to ≥3 of the following drugs: ceftazidime, ciprofloxacin, tobramycin, and imipenem) increased from 4% in 1993 to 14% in 2002. The lowest dual resistance rates were observed between aminoglycosides or fluoroquinolones with piperacillin-tazobactam while the highest were for those that included β-lactams and ciprofloxacin. Ongoing surveillance studies are crucial in monitoring antimicrobial susceptibility patterns and selecting empirical treatment regimens.

Sign in / Sign up

Export Citation Format

Share Document